These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34271072)
1. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. Vankadara S; Wong YX; Liu B; See YY; Tan LH; Tan QW; Wang G; Karuna R; Guo X; Tan ST; Fong JY; Joy J; Chia CSB Bioorg Med Chem Lett; 2021 Sep; 48():128263. PubMed ID: 34271072 [TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027 [TBL] [Abstract][Full Text] [Related]
3. A Patent Review on SARS Coronavirus Main Protease (3CL Chia CSB; Xu W; Shuyi Ng P ChemMedChem; 2022 Jan; 17(1):e202100576. PubMed ID: 34651447 [TBL] [Abstract][Full Text] [Related]
4. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors. Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853 [TBL] [Abstract][Full Text] [Related]
5. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403 [TBL] [Abstract][Full Text] [Related]
6. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659 [TBL] [Abstract][Full Text] [Related]
7. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151 [TBL] [Abstract][Full Text] [Related]
8. Discovery of SARS-CoV-2 3CL Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507 [TBL] [Abstract][Full Text] [Related]
9. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133 [TBL] [Abstract][Full Text] [Related]
10. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428 [TBL] [Abstract][Full Text] [Related]
11. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954 [TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies. Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476 [TBL] [Abstract][Full Text] [Related]
14. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083 [TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2. Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314 [TBL] [Abstract][Full Text] [Related]